Abstract:Background and Objective: Paraneoplastic neurological syndromes (PNS) are a group of rare syndromes associated with immunopathological process and tumors. Paraneoplastic autoantibodies are important for the diagnosis of PNS and for searching for underlying tumors. With the development of detection methods and discovery of new autoantibodies, the 2004 guidelines on PNS have recently been updated by a worldwide PNS-Care expert group. For clinicians, proper testing methods and testing results explanation are important for the diagnosis and treatment of PNS. This review aims to review the detection of paraneoplastic autoantibodies and the significance of testing results.Methods: We summarize the studies on detection methods, association of autoantibodies and PNS or tumors, particularly the guidelines of PNS.Key Content and Findings: Antibodies are divided into 3 groups in the context of PNS according to the frequency of cancer association regardless of their eventual pathogenic effect. Instead of well-characterized antibodies and partially-characterized antibodies, high-risk antibodies, intermediate risk antibodies and lower risk antibodies were applied. According to the location of recognized antigens, these autoantibodies are divided as anti-intracellular antigen antibodies and neuronal surface antibodies (NSAbs). Tissue-based assays is recommended as screening method for paraneoplastic antibodies. Moreover, this method is helpful to discover new autoantibodies. A combination of a screening method [tissue-based assays (TBA)] and a confirmatory test [immunoblot and cell-based assay (CBA)] can improve sensitivity and specificity of the tests. Many PNSs are associated with specific antineuronal antibodies, but there is considerable diversity. Some autoantibodies are markers of specific neurological syndromes. Paraneoplastic antibodies are often specific for the PNS-associated tumor rather than for a particular neurological syndrome.Conclusions: Diagnosis of PNS depends on integrated analysis of clinical manifestations and auxiliary examinations. During diagnosis, selection of candidate antibodies for testing is challenging due to the varying clinical phenotypes and tumors associated with a given antibody. Broad antibody panels are more likely to capture causative antibodies and should be considered. According to different subtypes of autoantibodies, specific tumors or PNS should be considered. However, antibody titers, including cerebrospinal fluid (CSF) titers, should not be the primary driver of treatment decisions.

Clinical analysis of 15 patients with paraneoplastic neurological syndromes caused by lung cancer

Clinical analysis of four patients with pulmonary artery sarcoma and literature review

The clinical, electrophysiological and nerve pathological features of paraneoplastic peripheral neuropathy

Case report: Immune checkpoint inhibitor-induced paraneoplastic neurological syndrome in two patients: a case series

Clinical Analysis of 28 Cases of Paraneoplastic Rheumatic Syndromes

Research progress in the diagnostic application of FDG PET/CT imaging in paraneoplastic neurological syndromes

Paraneoplastic neurological syndromes of small cell lung cancer

Paraneoplastic neurological syndrome and its impact on the treatment outcomes of small‐cell lung cancer: A single‐center retrospective analysis

Various clinical features of patients with anti-Hu associated paraneoplastic neurological syndromes: An observational study

Evaluation of the Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes in China

Myasthenia-like paraneoplastic syndrome with multiple cranial nerve tumor infiltration: A case report and literature review

Polymyositis as a paraneoplastic syndrome of a patient with primary pulmonary lymphoepithelioma-like carcinoma: a case report and literature review

Paraneoplastic syndrome mimicking adult-onset Still's disease caused by advanced lung cancer: a case report

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABAB R and Anti-Hu Paraneoplastic Neurological Syndromes

[Clinical characteristics of paraneoplastic retinopathy and optic neuropathy]

Detection of paraneoplastic antibodies and their significance in paraneoplastic neurologic syndromes: a narrative review

Lambert-Eaton Myasthenic Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report.

[Analysis of Clinical Characteristics of Lung Cancer Combined with Multiple Primary Malignancies in Other Organs]

Onconeuronal and antineuronal antibodies in patients with neoplastic and non-neoplastic pulmonary pathologies and suspected for paraneoplastic neurological syndrome

The Diagnostic Challenge of Small Cell Lung Cancer with Anti-Gamma-aminobutyric-acid B Receptor Encephalitis: a Case Report